业绩快报显示，受政策等因素影响，公司院内存量业务承压，而增量业务仍处于准入与成长期，对院内 业务收入产生直接影响。同时，零售终端受阶段性客流波动、行业竞争加剧、动销节奏有所放缓等因素 影响，加之精品国药板块部分产品尚处于渠道拓展阶段，受行业波动影响较为显著。 北京商报讯（记者 王寅浩 宋雨盈）2月6日，昆药集团发布2025年业绩快报，2025年实现营业收入65.77 亿元，同比下降21.72%；实现归属于上市公司股东的净利润3.5亿元，同比下降46%。 ...

Group 1 - ZTE Corporation plans to invest 200 million RMB to subscribe to the Guangdong-Hong Kong-Macao Greater Bay Area Venture Capital Guidance Fund, focusing on areas supported by national policies such as new generation information technology and biotechnology [1] - Huayi Jewelry's subsidiary has reported overdue loans totaling 200 million RMB due to tight liquidity, with a cumulative overdue principal of 254 million RMB [2] - Guangzhou Baiyunshan Pharmaceutical's subsidiary has received approval for the consistency evaluation of Alfacalcidol soft capsules, which are used to treat calcium metabolism disorders [3] Group 2 - Kunming Pharmaceutical Group reported a 21.72% decline in revenue to 6.577 billion RMB and a 46% drop in net profit to 350 million RMB for 2025 [4] - Jiantou Energy's application for a specific stock issuance has been approved by the Shenzhen Stock Exchange [5] - Jinchuan Titanium Industry's subsidiary has temporarily suspended its sulfuric acid production due to reduced demand [6] Group 3 - Kelun Pharmaceutical's subsidiary has received approval for a new indication for its antibody-drug conjugate, which is used to treat advanced hormone receptor-positive breast cancer [7] - Fawer Co., Ltd. has completed the relocation of its Chongqing Yuantai Shock Absorber Company and commenced production [8] - Jiuzhoutong's subsidiary has received acceptance for the listing application of Betahistine Hydrochloride tablets [9] Group 4 - Zhongguancun plans to build a traditional Chinese medicine and raw material drug production base in Jiamusi City, Heilongjiang Province [11] - China Wuyi announced that part of its land in Kenya has been requisitioned by the government, with compensation of approximately 6.25 million RMB [12] - Times Electric reported a 15.46% increase in revenue to 28.761 billion RMB and a 10.88% increase in net profit to 4.105 billion RMB for 2025 [13] Group 5 - Top Cloud Agriculture's shareholder has received regulatory measures from the Zhejiang Securities Regulatory Bureau for failing to timely disclose shareholding changes [14] - Xinwanda's subsidiary has reached a settlement in a lawsuit involving over 2.314 billion RMB, with an estimated impact of 500 to 800 million RMB on net profit for 2025 [15] - Dongrui Co., Ltd. reported a 25.19% increase in pig sales revenue in January, totaling 214 million RMB [16] Group 6 - Tianjin Tianshi reported a 3.08% decline in revenue to 8.236 billion RMB, while net profit increased by 15.68% to 1.105 billion RMB for 2025 [17] - Wantong Expressway plans to invest approximately 5.42 billion RMB in the renovation and expansion of the Lianhuo Expressway [18] - Qiaoyin Co., Ltd. has pre-qualified for a sanitation integration service project worth approximately 73.8 million RMB [20] Group 7 - Jindi Co., Ltd. plans to acquire 100% equity of Yuni Precision for 116 million RMB, focusing on precision stamping products [21] - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapeutic varieties [22] - Tongde Chemical has had some assets frozen due to a financing lease dispute [23] Group 8 - Zhongli Co., Ltd. is establishing an industrial fund with a total commitment of approximately 408.76 million RMB, focusing on new materials and artificial intelligence [24] - Tianbang Food reported a 9.93% increase in pig sales revenue in January, totaling 674 million RMB [25] - New Hope reported a 10.03% decrease in pig sales revenue in January, totaling 1.628 billion RMB [26] Group 9 - Tainkang's subsidiary has received a drug registration certificate for Minoxidil topical solution [27] - Lihua Co., Ltd. reported a 9.8% increase in chicken sales revenue in January, totaling 1.289 billion RMB [28] - Guojitong General reported a 45.71% increase in net profit to 58.52 million RMB for 2025 [29] Group 10 - Zhixin Co., Ltd. plans to invest up to 1.1 billion RMB in an automotive stamping and welding parts project [30] - Chuangyuan Technology's subsidiary has pre-qualified for a National Grid project worth approximately 94.77 million RMB [31] - Lisheng Pharmaceutical's adenine phosphate raw material has passed the listing application [32] Group 11 - Tongguang Cable's subsidiary has pre-qualified for a National Grid project worth approximately 108 million RMB [33] - Zhenghong Technology reported a 7.74% increase in pig sales revenue in January, totaling 14.35 million RMB [34] - Pengding Holdings reported a 0.07% decrease in consolidated revenue in January, totaling 2.701 billion RMB [35] Group 12 - Hongri Pharmaceutical has received approval for clinical trials of its injectable drug for acute pancreatitis [36][37] - Xinhua Medical has decided to terminate the acquisition of a 36.19% stake in Wuhan Zhongzhi Biotechnology [38] - Tianyu Bio reported an 11.23% decrease in pig sales revenue in January, totaling 54.29 million RMB [39]

格隆汇2月6日丨昆药集团(600422.SH)公布2025年度业绩快报，受前述多重因素影响，公司产品销售规 模及毛利率同比均有所回落，累计实现营业收入预计65.77亿元，较上年同期下降21.72%；实现归母净 利润预计3.5亿元，同比下降46%。公司非经常性损益预计为2.43亿元，同比增加6.1%，主要系参股企业 南京维立志博生物科技股份有限公司港股上市带动公司持有的相关金融资产公允价值变动损益及投资收 益同比显著增长，预计金额为1.19亿元；此外，计入当期损益的政府补助约0.7亿元，同比下降 24.15%。在归母净利润同比下降的情况下，由于非经常性损益同比仍保持增长，导致扣除非经常性损 益后的归母净利润同比降幅相应有所扩大。 ...

Core Viewpoint - The company, Kunming Pharmaceutical Group (600422.SH), reported a significant decline in both revenue and net profit for the fiscal year 2025, indicating challenges in its sales performance and profitability [1] Financial Performance - The company achieved a total revenue of approximately 6.577 billion yuan, representing a year-on-year decrease of 21.72% [1] - The estimated net profit attributable to shareholders is around 350 million yuan, reflecting a year-on-year decline of 46% [1] Sales and Profitability - The sales scale and gross profit margin of the company's products have both decreased compared to the previous year [1] Non-Recurring Gains - The company expects non-recurring gains to be approximately 243 million yuan, which is an increase of 6.1% year-on-year [1] - This increase is primarily driven by the listing of its associate company, Nanjing Weili Zhizhi Biotechnology Co., Ltd., on the Hong Kong Stock Exchange, leading to significant growth in the fair value changes and investment income of related financial assets, estimated at 119 million yuan [1] - Government subsidies included in the current period's profit are about 70 million yuan, which is a decrease of 24.15% year-on-year [1]

报告期，公司产品销售规模及毛利率同比均有所回落。公司非经常性损益预计为2.43亿元，同比增加 6.1%，主要系参股企业南京维立志博生物科技股份有限公司港股上市带动公司持有的相关金融资产公 允价值变动损益及投资收益同比显著增长，预计金额为1.19亿元;此外，计入当期损益的政府补助约0.7 亿元，同比下降24.15%。 智通财经APP讯，昆药集团(600422.SH)披露2025年度业绩快报，公司累计实现营业收入预计65.77亿 元，较上年同期下降21.72%;实现归母净利润预计3.5亿元，同比下降46%。 ...

证券代码：600422 证券简称：昆药集团 公告编号：2026-005号 昆药集团股份有限公司 2025 年度业绩快报 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2、上述数据以未经审计的合并报表数据填列，最终结果以公司 2025 年年度报告为准。 二、经营业绩和财务状况情况说明 2025年，公司处于外部环境复杂变化与内部模式深度转型的关键阶段，多重因素 1 叠加对业绩形成了阶段性影响。中成药集采实际执行进度不及预期、医保控费政策持 续深化，公司院内存量业务承受一定压力，而增量业务仍处于准入与成长期，对院内 业务收入产生直接影响。同时，零售终端受阶段性客流波动、行业竞争加剧、动销节 奏有所放缓等因素影响，加之公司精品国药板块部分产品尚处于渠道拓展阶段，受行 业波动影响较为显著。此外，公司内部渠道与模式变革正处于深化阶段，在品牌建设、 市场拓展等方面的持续战略性投入，短期内也进一步加剧了业绩压力。 特别提示：本公告所载 2025 年度的财务数据为昆药集团股份有限公司（以下简称 "公司"）初步核算数据，未经会计师事务所审计，与 ...

证券日报网讯2月5日，昆药集团（600422）在互动平台回答投资者提问时表示，公司严格遵守法律法规 及监管要求，如有达到信息披露标准的事项，将及时依规履行信息披露义务，敬请关注公司公告。 ...

Core Viewpoint - The company is actively focusing on the development trends of new retail channels and has initiated live streaming for its toothpaste products on platforms like Douyin and Taobao [1] Group 1: Company Strategy - The company is leveraging its "Chinese Time-Honored Brand" advantage to promote channel restructuring and brand building [1] - The company is emphasizing the promotion of chain terminals while continuously optimizing its national retail channel layout [1] Group 2: Market Adaptation - The company is dynamically adjusting product distribution and inventory strategies based on regional market demand [1] - The company aims to further enhance the market circulation efficiency of its products [1]

（文章来源：证券日报） 证券日报网讯 2月4日，昆药集团在互动平台回答投资者提问时表示，上市公司股价在二级市场的走势 及波动也受到包括行业政策在内的多重因素影响，敬请投资者注意投资风险。公司管理层始终高度专注 自身的经营管理，致力提升公司内在价值以回报广大投资者；同时，公司也通过多渠道、多方面与投资 者保持良性互动，积极向市场传递公司投资价值。 ...

证券日报网讯2月4日，昆药集团（600422）在互动平台回答投资者提问时表示，根据法律法规及监管要 求，公司的经营业绩情况将在法定披露渠道依法依规予以披露，敬请关注公司公告。 ...